N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants
N/A N=26 COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Pulmonary Valve Insufficiency · Pulmonary Valve Degeneration · Congenital Pulmonary Valve Abnormality
Primary: Percentage of Subject's With Freedom From Device or Procedure Related Death and/or Reoperation at 1-year Post-implant. — 100.0 percentage of subjects
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
N/A N=71 Portico Valve-in-Valve Retrospective Registry
Aortic Valve Stenosis · Aortic Valve Failure · Aortic Insufficiency
Primary: Primary Safety Endpoint: The Rate of All-cause Mortality, Disabling Stroke, Life-threatening Bleeding Requiring Blood Transfusion, Acute Kidney Injury (AKI) Requiring…
N/A N=50 Pulmonary Artery Repair With Covered Stents
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
Phase 2 N=3 Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)
Aortic Valve Stenosis
Primary: Total Work Performed During a Maximal-effort Exercise Test
N/A N=88 Behavior of Valve Leaflets Following Aortic Valve Implant
Aortic-valve Replacement
Primary: Reduction in Leaflet Motion — 12 Participants
N/A N=140 CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Pulmonary Valve Stenosis · Pulmonary Valve Insufficiency · Aortic Valve Stenosis
Primary: Hemodynamic Performance — 22.2; 13.5; 21.2; 21.9 mmHg
N/A N=190 Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)
Emphysema
Primary: Forced Expiratory Volume in 1-second (FEV1) — 61; 10 Participants
Phase 2 N=10 Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH
Pulmonary Arterial Hypertension
Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…
N/A N=30 Pleth Variability Index (PVI) as a Measure of Volume Status During Transcatheter Mitral Valve Repair
Mitral Regurgitation
Primary: Delta PVI to Delta LAP Correlation During MitraClip Placement — 4.30; -26.14 percentage of baseline (pre-MitraClip) — p=0.066
N/A N=756 Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve
Heart Valve Diseases
Primary: Incidence Rate of Adverse Events and Mortality for the Mitroflow Aortic Heart Valve Repair — 7.1; 1.27; 0.21; 0.56 Percent occurrence per patient-year
N/A N=208 Minimally Invasive or Conventional Edge-To-Edge Repair for Severe Mitral Regurgitation Due to Bileaflet Prolapse in Barlow's Disease: Does the Surgical Approach Have an Impact on the Long-term Results?
Barlow's Disease · Prolapse; Mitral
Primary: Cardiac Death — 3.9; 3.8 percentage of participants with event
N/A N=30 PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
N/A N=131 Melody® Transcatheter Pulmonary Valve Post-Approval Study
Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit
Primary: Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation — 96.7 percentage of patients
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
N/A N=18 Medtronic CoreValve REDO Study
Aortic Valve Stenosis
Primary: Percentage of MAE Free Subjects — 10 Participants
N/A N=197 PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve
Aortic Stenosis · Cardiomyopathy, Hypertrophic
Primary: Number of Participants With All-Cause Mortality, All Stroke, Moderate or Severe Obstruction, or Moderate or Severe Paravalvular Leak (Composite) — 28 Participants
N/A N=220 Edwards PASCAL Transcatheter Valve Repair System Registry
Mitral Valve Insufficiency
Primary: Major Adverse Events (MAEs) — 9; 2; 0; 1 Participants
N/A N=16 Pressure Variability Study
Heart Failure
Primary: Mean Change in Pulmonary Artery Pressure (PAP) Due to Change in Posture — 27.7 mmHg — p=0.429
N/A N=283 Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
Coronary Artery Disease · Aortic Valve Disorder · Heart Failure
Primary: Subject's Percentage of Long Term Safety Performance — 1.5; 2.7; 0.2; 0.4 Percentage of events/late patient years
Phase 2 N=55 Feasibility Study of a Percutaneous Mitral Valve Repair System.
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Mitral Regurgitation Severity — 0.0; 0.0; 5.6; 38.9 Percentage of participants
N/A N=65 Edwards CLASP TR EFS
Tricuspid Regurgitation
Primary: Composite Major Adverse Event (MAE) Rate — 6 Participants
N/A N=93 Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study
COPD Patients With Homogeneous Emphysema · Endoscopic Lung Volume Reduction With Endobronchial Valve
Primary: Percentage Change in Forced Expiratory Volume in 1 s (FEV1) (ITT Population) — 13.7; -3.2 percent change
N/A N=10 Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
Pulmonary Embolism
Primary: Change in Right Ventricle/Left Ventricle (RV/LV) Ratio — -0.4 Ratio
N/A N=171 Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort
Congenital Heart Defects · Dysfunctional Right Ventricular Outflow Tract Conduits
Primary: Kaplan-Meier Freedom From TPV Dysfunction — 72.9 percentage of subjects — p=<0.0001
N/A N=58 Treatment of IPF With Laparoscopic Anti-Reflux Surgery
Idiopathic Pulmonary Fibrosis · Gastroesophageal Reflux
Primary: Forced Vital Capacity (FVC) — -0.13; -0.05 liters
Phase 3 N=180 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis · Hypertension, Pulmonary
Primary: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement) — 9; 6 participants — p=0.39